Companies · Data / Analytics
Africa · Data / Analytics
Diligence memoA one-page analyst read on PBR Life Sciences — recommendation, valuation, rhythm, risks.→PBR Life Sciences has raised $1.0M over 1 round; too few niche peers to rank its valuation yet.
Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the data/analytics sector profile.
Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.
PBR Life Sciences is one of 41 Data / Analytics companies tracked from Africa. By capital raised it ranks in the upper tier (ahead of 88% of sector peers), and in the upper tier by modeled valuation est..
Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.
Nigerian e-health startup PBR Life Sciences has raised a US$1 million pre-seed funding round to scale its innovative data-as-a-service and analytics platform across Nigeria, Ghana, and Kenya.
Nigerian e-health startup PBR Life Sciences has raised a US$1 million pre-seed funding round to scale its innovative data-as-a-service and analytics platform across Nigeria, Ghana, and Kenya.
As reported in public records reported — not modeled.
Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.
The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.
Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.
Round size and date are reported; the stage label is inferred from round size (latest is Pre-Seed — a round under $1.0M). Valuation is modeled from stage benchmarks scaled by the data/analytics sector profile. Directional, not a quoted figure.
Not enough modeled valuation points to chart a trajectory.
Benchmarked against 41 companies in Data / Analytics. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.
Raised more than 88% of sector peers (real $). Modeled value above 78% of peers (estimate).
A tighter cohort than the sector chart above — only companies at the same stage (Pre-Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful.
Not enough valued peers in this cohort to chart positioning.
| Company | Stage | Raised · real | Value · est | vs peer med. |
|---|---|---|---|---|
| Estate Intel | Pre-Seed | $500K | $6.7M | 1.27× |
| PBR Life Sciences this company | Pre-Seed | $1.0M | $3.8M | 0.73× |
Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.
| Stage | Amount · real | Announced | Post-money · est | Value · est | Conf. |
|---|---|---|---|---|---|
| Pre-Seed | $1.0M | 2024-12-23 | $5.6M | $3.8M | 45% |
Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.
Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.
PBR Life Sciences is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.
Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.
| Company | Sector | Stage | Raised · real | Value · est | Why similar |
|---|---|---|---|---|---|
| Tremor Testing & Data Analytics, Inc. | Data / Analytics | Pre-Seed | $550K | $20.6M | same sector · same stage |
| Estate Intel | Data / Analytics | Pre-Seed | $500K | $6.7M | same sector · same stage |
| Big Data Analytics, Inc. | Data / Analytics | Pre-Seed | $252K | $11.4M | same sector · same stage |
| Zoios, Inc. | Data / Analytics | Seed | $1.5M | $8.5M | same sector |
| RNR | Data / Analytics | Growth/Late | $555K | $10.6M | same sector |
| Custora, Inc. | Data / Analytics | Series A | $10.7M | $316.3M | same sector |
| Artie, Inc. | Data / Analytics | Series B | $36.0M | $742.0M | same sector |
| Lever, Inc. | Data / Analytics | Series C | $69.1M | $1.1B | same sector |
See where PBR Life Sciences sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.
If you work at PBR Life Sciences, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.
Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.